MARKET NEWS

Lonza Expands Solid Form Screening Services for Accelerated Development of Small Molecule Drugs
Synairgen Announces Dosing Has Commenced With Its Inhaled Interferon Beta Product in US Government-Funded NIH ACTIV-2 Trial in COVID-19 Outpatients
Progenity Initiates Safety & Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases
Enlivex Announces Issuance of New US Patent Covering Methods of Treating Gout, Inflammatory Bowel Disease, Crohn’s Disease, Ulcerative Colitis & GvHD Using Allocetra Immunotherapy
Artelo Biosciences Announces Positive Pre-Clinical Data Associated With Proprietary CBD Cocrystal
Stevanato Group Leads First Industry Discussion Paper on Primary Container Traceability

  FEATURED EDITORIAL

  COMPANY PROFILE

The Sonceboz drug delivery device platform is designed for maximum flexibility for pharmaceutical companies with the goal to cover the full lifespan of a drug product starting from clinical trials to later lifecycle management activities. This is achieved by ensuring that existing fill and finish processes, primary containers and materials can be integrated seamlessly. Reduction of risk is one of the most important goals for pharmaceutical companies and by multiplying a device solution for different use-cases serves this purpose since the technology is established and well understood. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Halberd Collaborates With GreenBioAZ for the Development of Radio Frequency Technology to Eliminate Disease Pathogens

Halberd Collaborates With GreenBioAZ for the Development of Radio Frequency Technology to Eliminate Disease Pathogens

Halberd Corporation has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate….

SCYNEXIS Announces Licensing Agreement & Strategic Partnership With Hansoh Pharma

SCYNEXIS Announces Licensing Agreement & Strategic Partnership With Hansoh Pharma

SCYNEXIS, Inc. recently announced it has entered into a licensing agreement and strategic partnership with Hansoh Pharmaceutical Group Company Limited…..

Biomunex Pharmaceuticals Signs Strategic License & Co-development Agreement With Onward Therapeutics

Biomunex Pharmaceuticals Signs Strategic License & Co-development Agreement With Onward Therapeutics

Biomunex Pharmaceuticals and Onward Therapeutics SA recently announced the signing of a strategic exclusive worldwide license and co-development agreement for a proprietary….

Altimmune Announces FDA Clearance of Single-Dose, Needle-Free, Intranasal COVID-19 Vaccine Candidate

Altimmune Announces FDA Clearance of Single-Dose, Needle-Free, Intranasal COVID-19 Vaccine Candidate

Altimmune, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application for its Phase 1 clinical trial of AdCOVID….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

March 3 – Transdermal/Topical Delivery
March 10 – Particle Design Technology